Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of turoctocog alfa in previously treated patients with moderate or severe Haemophilia A in India
2017-002281-46Phase 4
- Sponsor
- Novo Nordisk
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Occurrence of confirmed FVIII inhibitor development (≥ 0.6 BU).
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2017-002281-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002281-46.